

IN THIS ISSUE...

IL-31 Expression by Inflammatory Cells is Preferentially Elevated in Atopic Dermatitis

In 2004, interleukin-31 (IL-31) was described as a short-chain 4-helix bundle cytokine that is expressed by activated CD4⁺ T cells, preferentially by T cells skewed toward a T_H2 phenotype (1). Recently it has been demonstrated that human mast cells (MC) are also a source of IL-31 (2). Moreover, monocytes, macrophages, immature and especially mature monocyte-derived dendritic cells produce IL-31 in response to ultraviolet (UV) irradiation and hydrogen peroxide (H₂O₂) treatment (3). Low IL-31 mRNA expression levels have been detected in tissues from testis, bone marrow, skeletal muscle, kidney, colon, thymus, small intestine and trachea (1). In normal human epidermal keratinocytes and dermal fibroblasts-enhanced IL31 mRNA expression is measured upon H₂O₂ stimulation (3). In the skin of NC/Nga mice with scratching behaviour, an animal model of atopic dermatitis (AD), expression of IL-31 mRNA was significantly higher than that in NC/Nga mice without scratching behaviour. Together, these findings suggest that IL-31 is associated with T_H2-driven

pruritic skin diseases, and that IL-31 may participate in the cause for itch sensation (4, 5).

IL-31 signals through a heteromeric receptor complex composed of the IL-31 receptor alpha (IL-31RA) and the oncostatin M receptor beta (OSMR) subunits. Engagement of the receptor complex results in activation of Janus kinase (JAK) tyrosine kinases and subsequently of different signalling molecules, including different signal transducers and activators of transcription (STAT) factors, as well as the MAPK and PI3K signalling pathways (Fig. 1). These pathways are activated in various cell types, including lung epithelial or malignant melanoma cells (6–8).

Expression of IL-31R α and OSMR β mRNA can be induced in activated monocytes, while their expression is constitutive in skin, testis and thymus, arguing that these organs are probably responsive to IL-31 (1, 9, 10). IL-31RA and OSMR β are also found co-expressed in a subset of neurons of murine and human dorsal root ganglia (9, 11), which represents the site where the soma of cutaneous sensory neurons are located, while their sensory fibres protrude directly into the skin. These sensory neurons might be implicated in the sensing




Fig. 1. Cytokine interleukin-31 (IL-31)-dependent signal transduction. (A) The IL-31 receptor is composed of IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMR). The domain structure of the two receptor subunits is indicated. Both have a C-terminal signalling peptide that is cleaved off during biosynthesis and translocation of the protein into the endoplasmic reticulum. IL-31 binds first to the IL-31RA (through two fibronectin III-like domains) and subsequently to the OSMR (through two fibronectin III-like and an immunoglobulin-like domain). Amino acids demonstrated to be important for binding are indicated; for binding to IL-31RA E44, E106, and H110; for binding to OSMR K134. The tyrosine residues that are phosphorylated by JAK kinases and mediate signalling are indicated. (B) Different cell types produce IL-31, as indicated; in many situations IL-31 production is regulated by different stimuli, including allergens, superantigens, and cytokines. The signalling that is stimulated is the JAK-STAT, the MAPK (i.e. ERK, p38 and JNK kinases), and the PI3K-AKT pathways. Of note is that IL-31RA activates predominantly different signal transducers and activators of transcription (STAT) molecules (purple), whereas OSMR is capable of stimulating all three pathways (green). These control downstream effectors, including transcriptional regulators that mediate and control IL-31-dependent target gene expression.

of itch and are possibly stimulated by IL-31. Recent studies demonstrated variations of IL-31RA expression in normal human epidermal keratinocytes that are dependent on the status of cellular differentiation and influenced by pro-inflammatory cytokines such as interferon-gamma (8).

While enhanced IL-31 mRNA expression has previously been detected in skin samples of inflammatory skin diseases such as AD, allergic contact dermatitis or prurigo nodularis (9, 12, 13), hardly anything is known about the protein expression of this cytokine in lesional skin from patients with inflammatory skin diseases. This question has now been addressed in an article in this issue of *Acta Dermato-Venereologica* by Nobbe and colleagues (p. 24–28) (14).

In their study they performed immunohistochemical staining for IL-31, IL-31RA and OSMR in formalin-fixed paraffin-embedded biopsy specimens of T_H1- and T_H2-weighted, pruritic and non-pruritic skin diseases. The authors demonstrate an enhanced IL-31 expression in biopsies of fresh lesions from patients with the extrinsic type of AD compared with controls. In 87% of samples from patients with AD cytoplasmic immunoreactivity for IL-31 was present in cells infiltrating the dermis, in contrast to epidermal cells, in which no significant staining could be detected (14). Comparisons of immunoreactivity in the dermal infiltrate of the examined itching skin diseases (AD, pruritus sine materia, psoriasis inverse, prurigo nodularis, Sézary syndrome, notalgia paraesthetica) revealed increased IL-31 immunoreactivity only in AD. Similar results were obtained by comparing different T_H2-weighted diseases (AD, localized alopecia areata, mycosis fungoides, Sézary syndrome), showing increased IL-31 immunoreactivity only in samples from subjects with AD.

These studies confirm, at the protein level, the relationship between IL-31 expression and AD that was previously identified at the mRNA level. However, the presented data do not support a general relationship between IL-31 protein expression and pruritic or T_H2-mediated diseases (14). Therefore IL-31 might play a role in the pathogenesis of AD and presents a putative therapeutic target, especially in the acute phase of this disease.

ACKNOWLEDGEMENTS

We would like to thank Christian Cornelissen for assisting in preparing Fig. 1. Work in the authors' laboratories has been supported by a grant of the Deutsche Forschungsgemeinschaft (SFB 542 project C11).

REFERENCES

1. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a

cytokine produced by activated T cells, induces dermatitis in mice. *Nat Immunol* 2004; 5: 752–760.

2. Niyonsaba F, Ushio H, Hara M, Yokoi H, Tominaga M, Takamori K, et al. Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. *J Immunol* 2010; 184: 3526–3534.
3. Cornelissen C, Brans R, Czaja K, Skazik C, Marquardt Y, Zwadlo-Klarwasser G, et al. Ultraviolet B (UVB) radiation and reactive oxygen species (ROS) modulate IL-31 expression in T-lymphocytes, monocytes and dendritic cells. *Br J Dermatol* 2011 Jun 28. [Epub ahead of print].
4. Takaoka A, Arai I, Sugimoto M, Honma Y, Futaki N, Nakamura A, et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. *Exp Dermatol* 2006; 15: 161–167.
5. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. *Eur J Pharmacol* 2005; 516: 180–181.
6. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. *Eur J Cell Biol* 2011 (in press).
7. Dreuw A, Radtke S, Pflanz S, Lippok BE, Heinrich PC, Hermans HM. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. *J Biol Chem* 2004; 279: 36112–36120.
8. Heise R, Neis MM, Marquardt Y, Jousen S, Heinrich PC, Merk HF, et al. IL-31 receptor alpha expression in epidermal keratinocytes is modulated by cell differentiation and interferon gamma. *J Invest Dermatol* 2009; 129: 240–243.
9. Sonkoly E, Muller A, Lauerma AI, Pivarsci A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol* 2006; 117: 411–417.
10. Dambacher J, Beigel F, Seiderer J, Haller D, Göke B, Auernhammer CJ, Brand S. Interleukin-31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is up-regulated in inflammatory bowel disease. *Gut* 2007; 56: 1257–1265.
11. Bando T, Morikawa Y, Komori T, Senba E. Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. *Neuroscience* 2006; 142: 1263–1271.
12. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. *J Allergy Clin Immunol* 2006; 118: 930–937.
13. Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewicz M, Yao L, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. *J Allergy Clin Immunol* 2006; 117: 418–425.
14. Nobbe S, Dziunycz P, Mühleisen B, Bilsborough J, Dillon SR, French LE, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. *Acta Derm Venereol* 2012; 92: 24–28.

Jens Malte Baron¹ and Bernhard Lüscher²

¹Department of Dermatology and Allergology and

²Institute of Biochemistry and Molecular Biology

RWTH Aachen University,

Pauwelsstraße 30,

DE-52074 Aachen, Germany